Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a model predict the right dose of rifampicin for bone infections?

NCT ID NCT07788404

Knowledge-focused Sponsor: Groupe Hospitalier Diaconesses Croix Saint-Simon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study looks at how the antibiotic rifampicin is processed by the body in people with staphylococcal bone and joint infections, such as prosthetic joint infections and chronic osteomyelitis. Researchers will take blood samples from 40 participants to measure drug levels and build a computer model that predicts how the drug behaves. The goal is to understand why responses vary and to help doctors choose the best dose for each patient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rifampicin, with levofloxacin or ciprofloxacin as partner antibiotics
What this could lead to
If successful, this could lead to more precise dosing of rifampicin for bone and joint infections, potentially improving treatment outcomes and reducing side effects.
What could go wrong
This is a small, single-center study focused on drug levels, not clinical outcomes. Results may not apply to all patients, and the model needs validation before changing practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient informed about the study and signed written consent obtained * Male or female participant aged 18 years or older * Staphylococcal osteoarticular infection (prosthetic joint infection of hip, knee, or shoulder; chronic osteomyelitis; or native joint infection) susceptible to rifampicin and levofloxacin or ciprofloxacin * Indication for combined medico-surgical treatment of the osteoarticular infection Exclusion Criteria: * Septic shock requiring vasopressor support * Prior rifampicin treatment within 1 month preceding inclusion * Contraindication to rifampicin (known allergy, major drug interaction, or hepatic cirrhosis) * End-stage renal disease on chronic dialysis * Pregnant or breastfeeding woman * Adult patient unable or unfit to give informed consent * Subject deprived of liberty by judicial or administrative decision * Subject not affiliated with or beneficiary of a national social security scheme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Native joint infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infective arthritis osteomyelitis periprosthetic joint infection staphylococcal infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteomyelitis Prosthetic joint infection Staphylococcal infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Groupe hospitalier Diaconesses Croix Saint Simon

    RECRUITING

    Paris, Paris, 75020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.